According to the Zhitong Finance APP, C&amp;Y Pharmaceutical (300254.SZ) announced that its subsidiary Hangzhou C&amp;Y Baoling Pharmaceutical Co., Ltd. has received the &#34;Drug Clinical Trial Approval Notice&#34; for &#34;Maltol Iron Capsules&#34; issued by the National Medical Products Administration. The company will conduct clinical trials in the near future.
Maltol Iron Capsules are suitable for the treatment of iron deficiency anemia in adults. Maltol Iron is a complex containing iron ions, which differs from iron salt compounds. When absorbed by the gastrointestinal tract, it dissociates, allowing iron ions and maltol to be absorbed separately. The iron ions are taken up by intestinal wall cells and transferred to transferrin and ferritin, thereby increasing the concentration of iron ions in serum, including ferritin and transferrin saturation, achieving the effect of iron supplementation. Unlike previous oral iron supplements based on iron salts, Maltol Iron can effectively reduce patients' intolerance to iron supplements. According to inquiries, there are currently no similar drugs approved for marketing in the domestic market

300254

C&Y Pharmaceutical's subsidiary Hangzhou C&Y Baoling Pharmaceutical Co., Ltd. recently received the clinical trial notification for "Maltol Iron Capsules" approved by the National Medical Products Administration and plans to conduct clinical trials. This drug is used to treat iron deficiency anemia in adults and has a lower intolerance rate, with no similar drugs approved for market in China

Zhitong

C&Y Pharmaceutical

Lifeon Pharmaceutical

TIBET AIM PHARM

CHINA RAILWAY

TY PHAR.

SHYNDEC

China Meheco

C&Y Pharmaceutical's subsidiary has received the clinical trial approval notice for maltol iron capsules